Production Capacity and Expansion - The company's gelatin and collagen production capacity reached 13,500 tons/year and 4,300 tons/year respectively, with full production requiring time due to market conditions and inventory levels, potentially impacting profits [9]. - The company plans to expand its production capacity with projects aimed at increasing gelatin production from 3,500 tons to 7,000 tons annually [33]. - The company is in the process of acquiring a 60% stake in Qingdao Yiqing Biotechnology Co., which will become a subsidiary upon completion of the acquisition [33]. - The company has increased its gelatin production capacity to 13,500 tons and collagen production capacity to 4,300 tons, maintaining a leading position in the industry [89]. Financial Performance - The company's operating revenue for the first half of 2021 was approximately ¥276.67 million, representing a 48.12% increase compared to ¥186.78 million in the same period last year [33]. - The net profit attributable to shareholders for the same period was approximately ¥7.55 million, an increase of 11.39% from ¥6.78 million year-on-year [33]. - The net profit after deducting non-recurring gains and losses decreased by 54.91% to approximately ¥1.73 million, down from ¥3.84 million in the previous year [33]. - The company's total assets at the end of the reporting period were approximately ¥1.69 billion, a 19.35% increase from ¥1.42 billion at the end of the previous year [33]. - The net assets attributable to shareholders increased by 40.78% to approximately ¥1.39 billion, compared to ¥989.96 million at the end of the previous year [33]. - The company reported a negative net cash flow from operating activities of approximately ¥6.67 million, a decline of 135.96% compared to a positive cash flow of ¥18.56 million in the same period last year [33]. - The basic earnings per share for the reporting period was ¥0.0142, reflecting a 10.08% increase from ¥0.0129 in the previous year [33]. Market Strategy and Development - The company aims to strengthen its market expansion efforts by collaborating with educational institutions and research organizations, focusing on product quality improvement and new product development [10]. - The company is actively seeking to develop strategic partnerships in economically developed regions to explore new sales paths for retail products [14]. - The company is focusing on the development of its collagen product line, targeting markets such as middle-aged and elderly consumers, women, and health-conscious individuals [14]. - The company recognizes the risks associated with potential mismatches between investment and returns in the retail product market and is taking steps to enhance brand building and market penetration [14]. - The company is committed to leveraging new consumption trends and expanding its market presence to meet evolving consumer demands [10]. Research and Development - The company is actively increasing investment in technological innovation and product development, particularly in small peptide applications to meet consumer upgrade demands [43]. - The company has made significant progress in key R&D projects, including the development of ultra-low endotoxin gelatin, which is aimed at the medical field and is expected to enhance the development of medical devices in China [79]. - The company has established key laboratories and research centers, including the first batch of key laboratories for gelatin in China [91]. - The company has published several research papers on gelatin and collagen peptides, contributing to its industry leadership in research and development [94]. Corporate Governance and Compliance - The company has established a robust internal control system to protect the rights of shareholders and creditors, ensuring compliance with relevant laws and regulations [152]. - The company has committed to avoiding any competitive products or similar businesses during the reporting period, ensuring compliance with the commitment made on June 28, 2021 [156]. - The company guarantees that its senior management will work exclusively for the listed company and will not hold positions in other companies controlled by the major shareholders [158]. - The company has established a sound corporate governance structure, ensuring independent operation and decision-making processes [158]. Environmental Responsibility - The company reported a total discharge of 147.61 tons/year of COD and 19.21 tons/year of ammonia nitrogen, all within the approved emission standards [146]. - The company has established an Environmental Protection Management Committee and implemented a comprehensive environmental monitoring plan to ensure compliance with environmental regulations [147]. - The company maintains a commitment to environmental protection, with no instances of exceeding pollution discharge limits reported [147]. - The company has received environmental impact assessment approvals for all construction projects, ensuring compliance with environmental standards [148]. Shareholder Engagement and Financial Management - The company will not distribute cash dividends, issue bonus shares, or increase share capital from reserves [16]. - The company has committed to fulfilling its obligations regarding immediate return measures to protect investor interests [162]. - The company plans to enhance market expansion efforts to increase sales revenue and future earnings [164]. - The company has initiated a share buyback program, with a budget of 100 million RMB, to enhance shareholder value and stabilize stock prices [193].

证券代码：300239 证券简称：东宝生物 公告编号：2021-064 包头东宝生物技术股份有限公司 关于举行2021年投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 包头东宝生物技术股份有限公司（以下简称"公司"）定于 2021 年 8 月 4 日（星期三）15：00—17：00 采用网络远程方式举行 2021 年投资者网上集体接 待日活动，现将有关事项公告如下： 本次投资者网上集体接待日活动将在深圳市全景网络有限公司提供的网上 平台采 用 网 络 远 程 的 方 式 举 行 ， 投 资 者 可 以 登 录 " 全 景 · 路 演 天 下 " （http://rs.p5w.net）参与本次互动交流。 欢迎广大投资者积极参与。 特此公告。 包头东宝生物技术股份有限公司 董事会 2021 年 7 月 29 日 ...

Financial Performance - The company's operating revenue for Q1 2021 was ¥138,178,161.95, representing a 53.56% increase compared to ¥89,993,866.50 in the same period last year[8] - Net profit attributable to shareholders was ¥4,628,670.64, up 36.59% from ¥3,508,687.40 in the previous year[8] - Basic and diluted earnings per share increased to ¥0.0089, reflecting a growth of 36.92% compared to ¥0.0067 in the previous year[8] - The company's net profit after deducting non-recurring gains and losses decreased by 10.31% year-on-year to CNY 2,282,380.49[23] - The net profit for the first quarter of 2021 was CNY 4,975,091.72, an increase of 76% compared to CNY 2,831,763.81 in the same period last year[63] - Operating profit reached CNY 6,343,741.66, up from CNY 3,525,775.07, reflecting a growth of 80% year-over-year[63] - The total profit amounted to CNY 6,347,193.29, compared to CNY 3,507,468.36 in the previous year, indicating a 81% increase[63] Cash Flow - The net cash flow from operating activities improved significantly to ¥3,278,714.69, a 209.95% increase from a negative cash flow of ¥2,350,379.61 in the same period last year[8] - Cash flow from operating activities generated a net amount of CNY 3,278,714.69, a significant recovery from a negative cash flow of CNY -2,982,028.40 in the prior year[67] - The net cash flow from investment activities was -11,965,847.06 CNY in Q1 2021, compared to -8,250,707.52 CNY in Q1 2020, indicating a decline in investment cash flow[71] - The net cash flow from financing activities was -8,059,928.22 CNY in Q1 2021, contrasting with a positive net cash flow of 18,883,375.32 CNY in Q1 2020[71] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,425,806,725.14, a slight increase of 0.56% from ¥1,417,934,200.36 at the end of the previous year[8] - Total liabilities increased to CNY 422,506,385.20 from CNY 419,750,969.84, reflecting a growth of about 0.60%[51] - The company's equity attributable to shareholders reached CNY 994,642,078.94, up from CNY 989,956,482.67, indicating an increase of approximately 0.17%[52] Shareholder Information - The total number of shareholders at the end of the reporting period was 30,374[12] - The largest shareholder, Inner Mongolia Dongbao Economic and Trade Co., Ltd., held 26.60% of the shares, totaling 138,823,422 shares[12] - The company did not engage in any repurchase transactions among the top 10 shareholders during the reporting period[13] Government Subsidies - The company received government subsidies amounting to ¥2,696,854.35, primarily related to asset-related government grants[9] - Cash received from government subsidies increased by 48.18% to CNY 2,599,306.80 compared to the previous period[22] Operational Costs and Expenses - The gross profit margin decreased due to a significant rise in operating costs, which amounted to ¥121,070,448.96, reflecting a 66.23% increase from ¥72,831,984.74[20] - Tax expenses increased by 79.48%, amounting to ¥2,181,946.29, due to higher sales leading to increased VAT and other taxes[20] - Selling expenses decreased by 39.30% to ¥2,135,151.99, as transportation costs were reclassified into operating costs under new revenue recognition standards[20] - Financial expenses surged by 135.50%, reaching ¥2,085,829.42, primarily due to increased interest on working capital loans[20] Future Outlook and Strategy - The company plans to continue expanding its product lines and market reach, focusing on gelatin and collagen products[20] - Future guidance indicates a positive outlook for revenue growth driven by increased sales volume and market demand[20] - The company plans to focus on innovation, operational strengthening, and new product promotion to drive growth[29] - The company aims to enhance product quality and development by collaborating with research institutions and downstream customers, focusing on new consumption trends and market expansion[31] Research and Development - The company is advancing the development of ultra-low endotoxin gelatin, aimed at applications in medical devices and tissue engineering[23] - A collaboration project with Shanghai Lanwei Medical Technology Co., Ltd. has been signed to expand the application of gelatin in high-value sectors[25] - The R&D project for artificial meat products has completed development, with a small production line in trial operation[27] - The company has initiated research on bioactive peptides derived from collagen, targeting applications in various fields[28] Production Capacity and Risks - The company has expanded its collagen production capacity to 13,500 tons/year for gelatin and 4,300 tons/year for collagen, but faces sales risks due to market conditions affecting full production ramp-up[30] - The company is addressing raw material procurement risks by optimizing supply chain management and exploring new sourcing channels[32] Compliance and Management - The company has received the "High-tech Enterprise Certificate" from relevant authorities, reaffirming its status as a high-tech enterprise[35] - The company is committed to improving its management efficiency and operational capabilities in response to the challenges posed by its expanded business scale[30] - The company has established a pandemic response team to mitigate the impact of COVID-19 on its operations and supply chain[34]

Financial Performance - The company's operating revenue for 2020 was approximately ¥448.83 million, a decrease of 8.79% compared to the previous year[30]. - The net profit attributable to shareholders for 2020 was approximately ¥18.45 million, representing a decline of 43.94% year-over-year[30]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥11.86 million, down 55.21% from the previous year[30]. - The net cash flow from operating activities for 2020 was approximately ¥63.13 million, a significant increase of 251.86% compared to the previous year[30]. - The total assets at the end of 2020 amounted to approximately ¥1.42 billion, reflecting a growth of 7.80% year-over-year[30]. - The net assets attributable to shareholders at the end of 2020 were approximately ¥989.96 million, showing a slight increase of 0.06% compared to the previous year[30]. - The basic earnings per share for 2020 were ¥0.0353, a decrease of 45.61% from the previous year[30]. - The diluted earnings per share for 2020 were also ¥0.0353, reflecting the same decline of 45.61% year-over-year[30]. - The company reported a quarterly revenue increase, with Q4 2020 revenue reaching approximately ¥147.76 million, the highest for the year[32]. - The company achieved total operating revenue of CNY 448,827,791.89, a decrease of 8.79% year-on-year[47]. Production Capacity and Expansion - The company's collagen production capacity reached 13,500 tons/year for gelatin and 4,300 tons/year for collagen, with potential short-term profit impacts due to fixed costs after project completion[8]. - The company has initiated projects to expand gelatin production capacity from 3,500 tons to 7,000 tons, which was affected by the pandemic[48]. - The company completed a 2000-ton collagen protein project and upgraded its production line from 1000 tons to 2300 tons, enhancing product quality and expanding capacity[77]. - The company plans to expand its collagen protein peptide supplement production capacity from 1,000 tons to 2,300 tons[123]. - The annual average net profit for the 2,000 tons collagen project is projected to be CNY 22.86 million once fully operational[132]. - The first-year capacity utilization rate for the 2,000 tons collagen project is expected to reach 60%, with an estimated net profit of CNY 8.319 million[132]. Research and Development - The company is committed to developing new products and enhancing quality to meet the evolving consumer demands in the market[9]. - The company is actively involved in the research and development of new technologies and products to lead innovation in the collagen field[50]. - Research and development expenditures have surged by 159.62% compared to the previous period, indicating a strong commitment to innovation[52]. - The company has obtained 19 authorized patents, including 11 Chinese invention patents and 1 U.S. invention patent, showcasing its focus on technological advancement[58]. - The company is focusing on enhancing product quality, R&D capabilities, and expanding application fields and marketing channels[44]. - The company is focusing on developing new health products in collaboration with top universities and research institutions, including projects related to low-endotoxin and antimicrobial peptides[148]. Market Strategy and Sales Channels - The company plans to enhance its market expansion efforts by collaborating with educational institutions and research organizations, aiming for breakthroughs in retail sales of collagen products[9]. - The company has established a sales platform in Hangzhou to promote retail product channel development and business expansion, leveraging both online and offline resources[14]. - The company is exploring new sales channels and partnerships in economically developed areas to improve retail product sales efficiency[14]. - The company is actively developing diverse sales channels, including retail and e-commerce, to capitalize on the growing health market[78]. - The company aims to leverage its trademark portfolio to enhance market penetration and brand recognition in competitive sectors[65]. Financial Management and Investments - The company has not planned to distribute cash dividends or issue bonus shares for the year[16]. - The company reported a total distributable profit of approximately 123.63 million RMB for the year[160]. - The company has committed to not infringing on the interests of shareholders, particularly minority shareholders, by not distributing dividends[164]. - The company has fulfilled all commitments made by actual controllers and shareholders during the reporting period[165]. - The company has made commitments to not interfere with its operational management and to protect its interests[176]. - The company will strictly implement its dividend policy to ensure shareholder returns[178]. Risk Management and Operational Efficiency - The company is focusing on optimizing its supply chain management to mitigate procurement price volatility risks, especially for key raw materials[12]. - The company is addressing management risks associated with its expanded operational scale by optimizing management models and forming core business teams[6]. - The company is committed to maintaining high standards in product safety and efficacy, as demonstrated by its research on the toxicological safety of collagen products[63]. - The company is committed to improving production, quality, and supply chain management while accelerating the certification process for key products and licenses[152]. Regulatory Compliance and Corporate Governance - The company has committed to ensuring that any new regulatory requirements from the China Securities Regulatory Commission will be met[167]. - The company has established a linkage between the execution of its compensation system and the measures to fill immediate returns[168]. - The company confirmed that all commitments made to minority shareholders were fulfilled on time[182]. - The company will comply with the latest regulations from the China Securities Regulatory Commission regarding shareholder and executive stock reduction[173]. Industry Trends and Market Position - The health and biopharmaceutical industry is experiencing rapid growth, supported by government policies and increasing consumer health awareness[49]. - The company’s market position is expected to improve as domestic technology levels and brand recognition increase, indicating significant growth potential in the collagen market[51]. - The company is benefiting from favorable government policies and the rapid development of the health service industry, which is expected to create better market opportunities for its collagen business[141]. - The company is positioned as a leading enterprise in the collagen industry, with a comprehensive production and sales system covering the entire collagen industry chain[140].

Financial Performance - Operating revenue for the current period was ¥114,287,205, representing a year-on-year increase of 5.75%[7] - Net profit attributable to shareholders decreased by 37.17% to ¥3,769,212.7 compared to the same period last year[7] - The basic earnings per share fell by 46.27% to ¥0.0072, while diluted earnings per share also decreased by the same percentage[7] - The company reported total operating revenue of CNY 301,069,330.26, a decrease of 11.22% compared to the same period last year[22] - Net profit attributable to shareholders was CNY 10,548,260.63, down 55.49% year-on-year[22] - The company reported a net profit margin improvement, with retained earnings at CNY 122,877,101.18 compared to CNY 129,758,258.26 in the previous period[52] - The total profit for the third quarter was CNY 4,365,565.00, down from CNY 7,008,213.04, reflecting a decline of about 37.5%[56] - The total profit for Q3 2020 was CNY 12.28 million, down 54.8% from CNY 27.16 million in Q3 2019[68] Cash Flow and Assets - The net cash flow from operating activities improved significantly, showing a 161.40% increase to ¥33,666,270[7] - The cash inflow from operating activities for the period was CNY 273,917,078.34, compared to CNY 202,614,268.60 in the previous period, representing a growth of approximately 35.2%[69] - The total cash outflow from investing activities was CNY 120,247,612.20, compared to CNY 134,285,688.90 in the previous period, indicating a decrease of about 10.5%[71] - The total cash and cash equivalents at the end of the period amounted to CNY 51,987,950.93, slightly down from CNY 54,365,916.23 at the end of the previous period[75] - Total assets at the end of the reporting period reached ¥1,403,113,232.85, an increase of 6.68% compared to the previous year[7] - As of September 30, 2020, the company's total current assets amounted to approximately CNY 490.33 million, an increase from CNY 474.11 million at the end of 2019[46] Liabilities and Equity - The company's net assets attributable to shareholders decreased by 0.49% to ¥984,196,581.94[7] - Total liabilities increased to CNY 416,749,651.14 from CNY 322,159,811.22 year-over-year[52] - Current liabilities rose to CNY 338,204,943.83, up from CNY 242,944,983.18 in the previous period[52] - The company's total equity decreased to CNY 987,235,706.03 from CNY 996,573,716.93[52] - The total equity attributable to shareholders of the parent company is CNY 989,082,880.93, indicating strong financial health[80] Inventory and Receivables - Inventory rose by 30.64% to ¥302,590,458.49, attributed to decreased sales during the COVID-19 pandemic[18] - Accounts receivable financing decreased by 81.22% to ¥12,311,132.31 from ¥65,551,538.90 due to the endorsement transfer of bank acceptance bills[18] - Accounts receivable decreased to CNY 88.52 million from CNY 102.40 million year-over-year, indicating improved collection efficiency[46] - Inventory levels increased significantly to CNY 302.59 million from CNY 231.62 million, reflecting a strategic buildup in anticipation of market demand[46] Research and Development - The company is advancing a new artificial meat project, with structural research nearly complete and equipment procurement underway[27] - The company is developing a super-low endotoxin gelatin preparation process, aimed at enhancing the medical device industry[29] - Research and development expenses were CNY 2,633,012.40, slightly down from CNY 2,648,127.86, indicating a focus on maintaining R&D investment[59] - Research and development expenses were CNY 8.34 million, slightly up from CNY 8.16 million year-over-year, showing continued investment in innovation[67] Shareholder Information - The total number of shareholders at the end of the reporting period was 30,117, with the largest shareholder holding 27.37%[10] - The company did not engage in any repurchase transactions among the top ten shareholders during the reporting period[12] - The company repurchased part of its restricted stock, reducing treasury stock by 50% to ¥2,536,560.00[19] Regulatory and Compliance - The company adjusted its financial statements to reflect the new revenue recognition standards, impacting contract liabilities and other current liabilities[81] - The company implemented new revenue recognition standards starting in 2020, adjusting advance payments to contract liabilities and other current liabilities[85] - The third quarter report was not audited[86]

Production Capacity and Expansion - The company has expanded its gelatin production capacity from 3,500 tons to 7,000 tons, with total annual gelatin capacity reaching 13,500 tons and collagen capacity at 3,000 tons[6]. - The company's construction of a 2,000-ton collagen production project has been completed, resulting in a 48.69% decrease in construction in progress compared to the beginning of the period[45]. - The annual production capacity for gelatin reached 13,500 tons, while collagen protein capacity was 3,000 tons following the launch of the fundraising project[61]. - The company is currently constructing several projects, including a 20,000-ton collagen protein peptide supplement production project, which is in the preparation stage[92]. - The company has committed to an investment project for the construction of a new gelatin production facility with an annual capacity of 3,500 tons, with a total investment of CNY 25,357 million, achieving 98.83% of the planned investment by the end of the reporting period[97]. Financial Performance - The company reported total operating revenue of ¥186,782,124.41, a decrease of 19.15% compared to the same period last year[26]. - Net profit attributable to shareholders was ¥6,779,047.92, down 61.70% year-on-year[26]. - The net profit after deducting non-recurring gains and losses was ¥3,844,553.20, a decline of 74.09% compared to the previous year[26]. - Basic earnings per share decreased to ¥0.0129, down 64.17% from the previous year[26]. - The weighted average return on net assets was 0.69%, a decrease of 1.35% compared to the previous year[26]. Market Strategy and Product Development - The company aims to strengthen its brand "Yuan Su Bone Peptide" in the senior market and has introduced new products such as "multi-flavor collagen peptide powder" and "fish collagen" to diversify its product line[8]. - The company is focusing on expanding into high-growth health markets, including nutrition and bone health, to capitalize on consumer trends[7]. - The company is enhancing its online marketing efforts, expanding into cross-border e-commerce and self-media channels to optimize its sales system[62]. - The company is focusing on market expansion in the fields of medicine, health, food, and beauty, aiming for diversified applications of collagen[60]. - The company has successfully developed new products, including a composite emulsifier and a new artificial meat project, indicating a diversification of collagen applications[51]. Challenges and Risks - The company has faced procurement risks due to increased costs from upstream suppliers and the ongoing impact of the pandemic, prompting it to strengthen its procurement strategies and explore new supply channels[11]. - The company faced challenges due to the COVID-19 pandemic, resulting in reduced demand from downstream customers and decreased international trade[40]. - Increased production costs were attributed to supply chain disruptions and higher procurement costs during the pandemic[41]. - The company emphasizes the importance of innovation and new product development to mitigate procurement price volatility risks[11]. Corporate Social Responsibility and Governance - The company has committed to corporate social responsibility by supporting pandemic relief efforts through donations and material support[13]. - The company emphasizes strict information disclosure and investor relations management, ensuring orderly operations under the new registration system[72]. - The company is committed to fulfilling its obligations regarding immediate return measures to protect investor interests[120]. - The company has made commitments to prevent any interference in its operational management by major shareholders[120]. Research and Development - The company has a strong focus on technological innovation, with 17 authorized patents, including 9 Chinese invention patents and 1 US invention patent[52]. - The company is committed to increasing R&D investment to support the industrialization and marketization of innovative projects[51]. - Research and development expenses were ¥6,415,004.61, down 41.99% from ¥11,058,175.06 in the previous year, due to the scheduling of R&D projects[74]. Environmental Compliance - The company has established an Environmental Protection Management Committee to oversee environmental compliance and pollution control measures[147]. - The company has not reported any major environmental incidents or exceedances of discharge limits during the reporting period[146]. - The company conducted annual emergency drills for environmental incidents to ensure preparedness and response capabilities[150]. Shareholder and Equity Management - The company did not distribute cash dividends or issue bonus shares during the reporting period[14]. - The company plans to continue its strategy of not distributing cash dividends or increasing share capital from capital reserves in the near term[114]. - The company has a three-year unlocking plan for equity incentive shares, with unlocking ratios of 40%, 30%, and 30%[162]. - The total number of ordinary shareholders at the end of the reporting period is 21,130[165].

Production Capacity and Expansion - The company has expanded its gelatin production capacity from 3,500 tons to 7,000 tons, with total gelatin capacity reaching 13,500 tons and collagen capacity at 3,000 tons[6]. - The company’s fixed assets increased by 31.40% compared to the beginning of the period, primarily due to the completion of the expansion project from 3,500 tons to 7,000 tons of gelatin production capacity[44]. - The company’s gelatin production capacity increased to 13,500 tons per year, while collagen production capacity rose to 3,000 tons per year, further solidifying its industry-leading position[43]. - The annual production capacity of gelatin was expanded from 3,500 tons to 7,000 tons, with the project completed in December 2019, achieving 100% of the planned investment[114]. Financial Performance - The company’s operating revenue for 2019 was CNY 491,819,372.27, representing an increase of 8.63% compared to CNY 452,748,251.38 in 2018[26]. - The net profit attributable to shareholders for 2019 was CNY 35,607,138.71, a growth of 4.80% from CNY 33,977,157.88 in the previous year[26]. - The net profit after deducting non-recurring gains and losses decreased by 14.44% to CNY 26,011,731.69 from CNY 30,401,690.85 in 2018[26]. - The net cash flow from operating activities was negative at CNY -41,633,068.00, a decline of 169.39% compared to CNY 60,001,285.47 in 2018[26]. - The total assets at the end of 2019 amounted to CNY 1,314,347,774.95, reflecting a 9.64% increase from CNY 1,198,743,162.74 in 2018[26]. - The net assets attributable to shareholders increased by 32.09% to CNY 991,864,420.48 from CNY 750,879,458.49 in 2018[26]. - The basic earnings per share for 2019 was CNY 0.0704, a decrease of 4.48% from CNY 0.0737 in 2018[26]. - The weighted average return on equity for 2019 was 3.85%, down from 4.61% in 2018[26]. Product Development and Innovation - The company launched a new product line, including collagen peptide juice drinks, targeting the elderly and female markets, amidst intense competition in the consumer goods sector[8]. - The company is focusing on new product development and market expansion in health sectors, particularly in nutrition and bone health markets[7]. - The company successfully developed a new product, compound bone collagen (compound emulsifier), aimed at improving the quality and protein content of frozen and prepared meat products[64]. - The company has developed a collagen peptide preparation method that inhibits cancer cell proliferation, which is crucial for its strategic positioning in the pharmaceutical market[52]. - The company has obtained 3 new invention patents and 1 design patent during the reporting period, enhancing its technological innovation capabilities[66]. Market Strategy and Customer Engagement - The company aims to enhance its brand "Yuan Su Bone Peptide" in Inner Mongolia and surrounding areas, while also expanding its retail collagen protein market share through strategic partnerships[9]. - The company is enhancing its e-commerce and new retail channels to boost sales and customer engagement through a "partner" mechanism[9]. - The company has signed a cooperation agreement with Yicheng (Zhejiang) Trading Co., Ltd. to expand its retail product market[70]. - The company is actively pursuing strategic customer acquisition to solidify its core advantages in the collagen market[135]. - The company plans to enhance its market share by advancing strategic alliances and focusing on differentiated competition in niche markets such as special-purpose gelatin and halal products[135]. Research and Development - The company has invested significantly in R&D, ranking among the top in the industry, and has established stable partnerships with institutions like the Chinese Academy of Sciences to enhance technological advancements[50]. - The company holds 20 authorized patents, including 11 Chinese invention patents and 1 U.S. invention patent, which support its strategic development in the pharmaceutical health sector[52]. - The company has established several research platforms, including key laboratories and technology centers, to bolster its R&D capabilities and innovation[50]. - The company’s R&D investment for the reporting period is ¥17,330,078.65, representing a year-on-year increase of 3.21%[87]. - The number of R&D personnel is 73, making up 10.20% of the total workforce[88]. Risk Management and Operational Strategies - The company is facing procurement risks due to increased costs and supply chain disruptions caused by the pandemic, prompting measures to secure quality raw materials[10]. - The company is committed to optimizing its procurement management to control costs and mitigate risks associated with raw material price fluctuations[10]. - The company has established a pandemic response team to monitor and adjust operational strategies to mitigate the impact of COVID-19 on its business[12]. - The company is focusing on automation and intelligent transformation projects to reduce costs and improve efficiency[70]. - The company has a well-defined emergency response plan for environmental incidents, with annual drills conducted[191]. Corporate Governance and Compliance - The company has made commitments to avoid transferring benefits to other entities or individuals in an unfair manner[152]. - The company has adhered to regulations regarding the reduction of shareholdings by shareholders and senior management[152]. - The company has committed to not engaging in any competing business after its listing[158]. - The company has fulfilled its commitments made during the asset restructuring and non-public issuance of shares, including a lock-up period for newly issued shares[151]. - The company has maintained a continuous audit service with Da Hua Accounting Firm for 8 years[164]. Social Responsibility and Environmental Compliance - The company emphasizes social responsibility, focusing on economic and social benefits while protecting investor rights[184]. - The company donated products worth over 200,000 RMB to support COVID-19 prevention efforts in Baotou[186]. - The company has established an Environmental Protection Management Committee to oversee compliance with environmental regulations[188]. - The company adheres to the national wastewater discharge standards, ensuring no exceedance of pollutant limits[188]. - The company has received multiple honors for its contributions to social welfare and public image[186].

Financial Performance - Total revenue for Q1 2020 was ¥89,993,866.50, a decrease of 20.56% compared to ¥113,291,169.46 in the same period last year[8] - Net profit attributable to shareholders was ¥3,508,687.40, down 53.91% from ¥7,612,512.42 year-on-year[8] - Basic earnings per share decreased by 59.39% to ¥0.0067 from ¥0.0165 in the same period last year[8] - Operating profit was ¥4,202,698.66, down 52.03% year-on-year, while total profit decreased by 52.27% to ¥4,184,391.95[21] - The company reported a net profit of CNY 128,557,649.21, compared to CNY 125,048,961.81 in the previous period, reflecting a growth of approximately 2%[53] - The net profit for the first quarter was CNY 3,508,687.40, down from CNY 7,612,512.42 in the same period last year, representing a decline of about 54%[60] Cash Flow and Liquidity - Net cash flow from operating activities was negative at ¥-2,350,379.61, a decline of 109.13% compared to ¥25,732,244.52 in the previous year[8] - The cash inflow from operating activities was CNY 83,080,412.66, compared to CNY 74,930,997.10 in the previous period, marking an increase of approximately 11%[67] - The total cash outflow from investing activities was 8,250,707.52 yuan, resulting in a net cash flow from investing activities of -8,250,707.52 yuan[72] - The company had a cash increase of 10,611,523.01 yuan during the period, compared to an increase of 189,203,548.49 yuan in the previous period[72] - Total cash and cash equivalents at the end of the period amounted to 61,002,902.85 yuan, down from 250,614,218.96 yuan in the previous period[72] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,339,475,006.30, an increase of 1.91% from ¥1,314,347,774.95 at the end of the previous year[8] - Total liabilities rose to CNY 343,611,088.86 from CNY 322,159,811.22, representing an increase of approximately 6.9%[56] - The total equity of the company reached CNY 999,572,400.74, up from CNY 996,573,716.93, a slight increase of about 0.2%[56] - The total current liabilities were CNY 242,944,983.18, with accounts payable at CNY 143,766,630.86[79] Investment and R&D - R&D expenses increased compared to the previous year, indicating a focus on innovation despite revenue challenges[22] - The company officially launched the "annual production of 2000 tons of collagen protein project," increasing collagen production capacity to 3000 tons/year[30] - The acquisition of Dongbao Datian Bio-Tech Co., Ltd. was completed, enhancing resource utilization and optimizing the company's industrial layout[27][28] - Research and development expenses increased to CNY 2,916,046.19 from CNY 2,618,974.35, showing a growth of about 11%[63] Market and Product Development - The company is advancing the marketization of a new emulsifier product aimed at the frozen prepared meat sector, with plans for significant sales within the year[29] - The company launched a new product line, including collagen peptide juice drinks, targeting the elderly and female markets, amidst a competitive retail environment[33] - The company is focusing on expanding the collagen protein market, leveraging its strong product quality and customer base[30] - The company aims to enhance its brand presence in Inner Mongolia and surrounding areas, leveraging national policies to increase market share in retail collagen products[34] Challenges and Risks - The impact of the COVID-19 pandemic has led to reduced sales volume and increased procurement costs, affecting overall profitability[21] - The company is facing risks related to raw material procurement due to increased costs and supply chain disruptions caused by the pandemic[35] - The company is exploring new sales channels, including e-commerce and community retail, to adapt to changing market conditions and consumer behavior[34] Corporate Governance and Social Responsibility - The company is committed to corporate social responsibility by donating materials and supporting pandemic relief efforts[38] - The company has established a pandemic response team to monitor and adjust operational strategies to mitigate the impact of COVID-19 on production and sales[37] - The company is actively participating in industry standard formulation to enhance product quality and market competitiveness in response to regulatory challenges[36] Financial Reporting and Compliance - The company reported no significant changes in project feasibility during the reporting period[42] - There were no violations regarding external guarantees or non-operating fund occupation by controlling shareholders during the reporting period[44][45] - The first quarter report was not audited, which may affect the reliability of the financial data presented[81]

Financial Performance - Operating revenue for the reporting period was ¥108,075,675.55, representing a year-on-year increase of 17.32%[8] - Net profit attributable to shareholders of the listed company was ¥6,179,054.09, up 2.90% compared to the same period last year[8] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥5,500,175.84, a slight increase of 0.83% year-on-year[8] - Basic earnings per share for the reporting period were ¥0.0134, an increase of 3.88% year-on-year[8] - The company achieved a revenue of CNY 339,104,382.18 in the first three quarters of 2019, representing a year-on-year growth of 5.22%[25] - Operating profit for the same period was CNY 27,576,557.83, an increase of 2.67% compared to the previous year[25] - The total profit amounted to CNY 30,073,895.18, reflecting a growth of 12.03% year-on-year[25] - The net profit attributable to shareholders reached CNY 25,872,173.47, marking a 13.55% increase from the previous year[25] - The total operating income for the year-to-date period was ¥339,104,382.18, up from ¥322,296,512.05, indicating a growth of approximately 5.2%[62] - The total operating costs for the year-to-date period were ¥314,894,718.74, compared to ¥296,253,938.21 in the previous year, which is an increase of about 6.3%[62] Assets and Liabilities - Total assets at the end of the reporting period reached ¥1,250,215,773.63, an increase of 4.29% compared to the end of the previous year[8] - Net assets attributable to shareholders of the listed company amounted to ¥982,713,675.24, reflecting a growth of 30.88% year-on-year[8] - Total current assets decreased to CNY 466.5 million from CNY 477.2 million, a decline of approximately 1.5%[46] - Total non-current assets increased to CNY 783.71 million from CNY 721.54 million, an increase of approximately 8.6%[46] - Total liabilities decreased to CNY 267.50 million from CNY 447.86 million, a decrease of approximately 40.2%[47] - Total equity increased to CNY 982.71 million from CNY 750.88 million, an increase of about 30.8%[48] - The company reported a total liabilities decrease to CNY 267,204,067.60 from CNY 447,188,265.71 year-over-year[53] - The total assets of the company reached CNY 1,255,289,411.45, compared to CNY 1,207,908,499.37 in the previous year[53] Cash Flow - The net cash flow from operating activities showed a significant decline, amounting to -¥55,624,350.37, a decrease of 405.16% compared to the previous year[8] - Cash flow from operating activities showed a net outflow of ¥55,624,350.37, contrasting with a net inflow of ¥18,228,225.75 in the same period last year[73] - Investment activities resulted in a net cash outflow of ¥133,876,970.61, compared to a smaller outflow of ¥25,829,582.16 in the previous year[73] - Financing activities generated a net cash inflow of ¥189,647,263.66, significantly higher than the previous year's inflow of ¥35,350,255.93[73] - The ending cash and cash equivalents balance was ¥67,295,696.78, down from ¥81,931,267.51 in the previous year[73] Research and Development - The company has established a strong focus on R&D, with 12 research labs dedicated to various aspects of collagen and gelatin applications, resulting in 3 new authorized invention patents in 2019[28] - The purification and separation project for bone collagen peptides has shown promising results, indicating that the isolated small peptides promote the proliferation and differentiation of osteoblasts[29] - The company has confirmed the experimental plan for the second animal trial in the study of the tumor-inhibiting mechanism of bone collagen peptides, with patents granted in both China and the US[30] - The electrospun gelatin fiber hemostatic material project is progressing, with the purification plant completed and product registration preparations underway, aiming for production by the end of the year[31] - The development of ultra-low endotoxin gelatin preparation technology is underway, targeting applications in absorbable hemostatic cotton and tissue engineering scaffolds[32] Market Expansion and Product Development - The company is actively pursuing market expansion in the health and beauty sectors, including the development of collagen-based skincare products[27] - The company has successfully developed a new product, "compound bone collagen," primarily used in the frozen prepared meat processing industry, and has obtained the necessary food production license[36] - The company is committed to high-quality development, focusing on the "medical, food, beauty, and health" sectors to enhance product value and meet market demands[35] - The company has initiated research on the high-tech applications of collagen protein in various fields, including biomedicine and food packaging[33] Financial Management - The company's financial expenses decreased by 77.92% to CNY 387,562.32, attributed to reduced bank loans[21] - The company reported a financial expense of -CNY 44,773.89, a significant improvement from CNY 675,494.83 in the previous period[55] - Financial expenses decreased significantly to -¥33,225.44 from ¥675,963.71, indicating improved financial management[59] - The company has implemented a clear and stable cash dividend policy, ensuring transparency and protecting shareholders' rights[39]

Financial Performance - The total operating revenue for the reporting period was CNY 231,028,706.63, a 0.37% increase compared to the same period last year [24]. - The net profit attributable to shareholders of the listed company was CNY 19,693,119.38, representing a 17.36% increase year-on-year [24]. - The net cash flow from operating activities was CNY -49,622,167.79, a decrease of 330.35% compared to the previous year [24]. - The total assets at the end of the reporting period amounted to CNY 1,292,473,846.60, an increase of 7.82% from the end of the previous year [24]. - The net assets attributable to shareholders of the listed company reached CNY 976,117,321.15, reflecting a 30.00% increase compared to the previous year [24]. - The company achieved an operating profit of CNY 20,314,562.63, which is a 1.61% increase from the previous year [34]. - The three period expenses (selling, administrative, and financial expenses) decreased by 4.19% to CNY 20,395,594.52 compared to the previous year [34]. - The company reported a total investment of RMB 74,085.8 million in various projects, with RMB 58,448.9 million already utilized, representing a utilization rate of 78.8% [86]. - The total liabilities decreased to CNY 316,356,525.45 from CNY 447,863,704.25, reflecting a reduction of approximately 29.39% [171]. - The total equity increased to CNY 982,591,679.49 in the first half of 2019, compared to CNY 760,720,233.66 in the same period of 2018, marking a growth of 29.2% [176]. Investment and Expansion - The company raised a total of RMB 232.2 million from a private placement, with the net proceeds allocated entirely to investment projects, aiming for an annual production capacity of 13,500 tons of gelatin and 3,000 tons of collagen after project completion [6]. - The expansion project for gelatin production capacity from 3,500 tons to 7,000 tons is nearing completion, with equipment debugging currently underway [6]. - The company is expanding its production capacity with a project to increase gelatin output from 3,500 tons to 7,000 tons and a new collagen protein project with an annual capacity of 3,000 tons [52]. - The company has invested RMB 36,073,000.00 in a collagen project, with 70.00% of the funding utilized as of the reporting period [80]. - The company has a project for a collagen industry demonstration base, with an investment of RMB 8,572,050.00, which is 78.00% funded [80]. - The company plans to accelerate the investment progress of fundraising projects to quickly realize expected benefits [104]. Research and Development - The company is actively investing in R&D, with a focus on new product development and technology innovation to meet market demands [43]. - The company has developed a patented method for producing collagen peptides with anti-cancer properties, which is expected to enhance its position in the pharmaceutical health sector [45]. - The company has made significant progress in R&D, including the development of a new medical cold compress product and advancements in collagen peptide purification [54]. - Research and development investment surged by 176.86% to RMB 11.06 million, reflecting the company's commitment to enhancing its R&D capabilities [65]. - The company is focusing on research and development of new products and technologies to enhance its market position [138]. Market Strategy - The company plans to enhance market expansion efforts, particularly in the rapidly growing health markets, leveraging the high-quality characteristics of its collagen products [7]. - The company aims to strengthen its brand "Yuan Su Bone Peptide" in Inner Mongolia and surrounding areas, while also developing e-commerce and micro-business channels to increase market share [9]. - The company is focusing on expanding its collagen business, particularly in the Hangzhou market, and is actively engaging in resource integration and partnerships [59]. - The company is committed to aligning its development strategy with the growing health market, particularly in small molecule peptide products [51]. - The company is responding to market challenges by expanding its customer base and exploring new application areas for its products [57]. Financial Management - The company does not plan to distribute cash dividends or issue bonus shares, focusing on reinvestment for growth [12]. - The company has established a comprehensive procurement management system to control supplier selection and procurement costs effectively [10]. - The company is actively investing in high-quality bone particle bases to mitigate procurement price volatility risks associated with raw materials [10]. - The company has implemented a centralized procurement management system to ensure product quality and safety [33]. - The company has made commitments to avoid any competition with its own products and businesses [107]. Environmental and Regulatory Compliance - The company has established an environmental protection management committee and implemented comprehensive environmental monitoring and management systems to ensure compliance with environmental regulations [130]. - The company has successfully maintained all pollutant emissions within the approved limits, with no instances of exceeding discharge standards [130]. - The company reported a total COD discharge of 106.559 tons and ammonia nitrogen discharge of 10.603 tons during the reporting period, adhering to the national wastewater discharge standards [129]. - The company has established emergency response plans for environmental incidents, ensuring preparedness for potential pollution accidents [131]. - There were no penalties or rectification measures required during the reporting period, indicating compliance with regulations [116]. Shareholder and Corporate Governance - The company has committed to fulfilling its obligations to minority shareholders, ensuring timely execution of promises made [109]. - The company has made a commitment to not use company assets for investments unrelated to its responsibilities, ensuring the protection of company interests [102]. - The company has successfully fulfilled its commitments related to the non-public offering of shares, which includes a total of 33,600,000 shares [100]. - The company has ensured that its commitments regarding the non-transfer of shares are being executed normally, with no overdue obligations as of the reporting period [100]. - The company has appointed a new financial director, Hao Haiqing, on April 17, 2019, following the resignation of the previous financial director [161].